Compare SIGA & BGH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SIGA | BGH |
|---|---|---|
| Founded | 1995 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 309.8M | 278.7M |
| IPO Year | 2016 | 2011 |
| Metric | SIGA | BGH |
|---|---|---|
| Price | $3.64 | $14.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 488.9K | 92.7K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | ★ 13.24% | 10.06% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $224.81 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.56 | $13.19 |
| 52 Week High | $9.62 | $16.90 |
| Indicator | SIGA | BGH |
|---|---|---|
| Relative Strength Index (RSI) | 23.13 | 52.94 |
| Support Level | N/A | $14.00 |
| Resistance Level | $4.84 | $15.25 |
| Average True Range (ATR) | 0.15 | 0.15 |
| MACD | -0.07 | 0.02 |
| Stochastic Oscillator | 8.14 | 63.30 |
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.
Barings Global Short Duration High Yield Fund is a diversified, closed-end management investment company. Its investment objective is to seek as high a level of current income as the Adviser determines is consistent with capital preservation. The Fund seeks capital appreciation as a secondary investment objective when consistent with its primary investment objective. Under normal market conditions, the Fund will invest at least 80% of its Managed Assets in bonds, loans and other income-producing instruments that are, at the time of purchase, rated below investment grade.